Illumina (ILMN)
(Delayed Data from NSDQ)
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?
by Zacks Equity Research
Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.
What Falling Estimates & Price Mean for ChromaDex (CDXC)
by Zacks Equity Research
ChromaDex (CDXC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
by Zacks Equity Research
Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100
by Zacks Equity Research
Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
by Zacks Equity Research
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
ResMed Releases Positive U.S. & U.K. Study Data on COPD
by Zacks Equity Research
ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains ground on product launches and international prospects.
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
by Zacks Equity Research
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)?
by Sweta Killa
Sector ETF report for PBE
QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.
Medtronic Initiates Study on DES for Expanded Use in the US
by Zacks Equity Research
Medtronic (MDT) focuses on boosting CSH segment. Notably, successful results from The Bifurcation Cohort study will help the company to achieve expanded FDA approval for the Resolute Onyx DES.
Illumina Takes Over Edico Genome, Fortifies NGS Platform
by Zacks Equity Research
Illumina (ILMN) proceeds with deals to boost NGS platform.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
by Zacks Equity Research
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
by Zacks Equity Research
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
5 Winning Stocks With Superb Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina
Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View
by Zacks Equity Research
Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.
5 Top Stocks Showing Promise of an Earnings Beat
by Zacks Equity Research
Bet on five stocks that are likely to outdo earnings estimates.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
4 Top Efficient Stocks to Buy for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.